Figure (Pal0h 0002 01)
Palsonify Tablet, Film Coated
Product Images NDC 84015-920
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Palsonify (NDC 84015-920). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Crinetics Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (Pal0h 0002 02)
This text is a prescription label for a medication called Palsonify, which is in tablet form. Each tablet contains 20 mg of paltusotine hydrochloride. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F). The prescription information advises to consult the full prescribing information for dosage details and to keep the medication out of reach of children. The medication is manufactured by Crinetics Pharmaceuticals, Inc. in San Diego, CA. The label includes details on the NDC code, quantity of tablets (60 tablets), and other important information for its use.*
Principal Display Panel (Pal0h 0002 03)
This text is a product label for tablets containing paltusotine hydrochloride. Each tablet contains 30 mg of paltusotine. The tablets should be stored between 20°C to 25°C. The product is manufactured by Crinetics Pharmaceuticals, Inc. in San Diego, CA. It is recommended to keep the tablets out of reach of children. The dosage information is available in the full prescribing information. The product is meant for oral use and comes in a pack of 60 tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
